[HTML][HTML] Safety considerations for withdrawal of nucleos (t) ide analogues in patients with chronic hepatitis B: First, do no harm
Nucleos (t) ide analogues (NA) are widely used to treat hepatitis B virus (HBV) infection, but
they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at …
they cannot eradicate the virus and treatment duration can be lifelong if the endpoint is set at …
Finite nucleos (t) ide-analogue therapy for functional cure in HBeAg-negative chronic hepatitis B: recent development in the paradigm shift
YF Liaw, G Papatheodoridis - Hepatology, 2024 - journals.lww.com
Long-term nucleos (t) ide analogue (Nuc) therapy in chronic hepatitis B (CHB) may lead to
hepatitis B virus (HBV) suppression, alanine aminotransferase (ALT) normalization …
hepatitis B virus (HBV) suppression, alanine aminotransferase (ALT) normalization …
Severe hepatitis B flares with hepatic decompensation after withdrawal of nucleos (t) ide analogues: a population‐based cohort study
Background Finite nucleos (t) ide analogue (NUC) therapy has been proposed as an
alternative treatment strategy for chronic hepatitis B (CHB). Aim To quantify the incidence of …
alternative treatment strategy for chronic hepatitis B (CHB). Aim To quantify the incidence of …
[HTML][HTML] Predictors of hepatic flares after nucleos (t) ide analogue cessation–Results of a global cohort study (RETRACT-B study)
Background & Aims Flares after nucleos (t) ide analogue (NA) cessation are common and
potentially harmful. Predictors of flares are required for risk stratification and to guide off …
potentially harmful. Predictors of flares are required for risk stratification and to guide off …
[HTML][HTML] Unmet needs in the clinical management of chronic hepatitis B infection
PD Block, JK Lim - Journal of the Formosan Medical Association, 2024 - Elsevier
The hepatitis B virus (HBV) remains a global problem despite effective tools to prevent,
diagnosis, and control it. Unmet needs are identifiable across its clinical care cascade …
diagnosis, and control it. Unmet needs are identifiable across its clinical care cascade …
Benefits of stop** therapy in patients with cirrhotic hepatitis B, true effect or residual confounding?
We have read with great interest the article by Jeng et al [1] in which they reported a
decreased HCC risk and mortality rate in patients with cirrhosis who stopped nucleo (s) tide …
decreased HCC risk and mortality rate in patients with cirrhosis who stopped nucleo (s) tide …
Why and when could nucleos (t) ide analogues treatment be withdrawn?
Oral antiviral therapy to hepatitis B virus (HBV) with nucleos (t) ide analogues (NUCs) is
effective in suppressing the viral load leading to improved clinical outcomes. However …
effective in suppressing the viral load leading to improved clinical outcomes. However …
Early HBcrAg and Anti‐HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos (t) ide Analogue Cessation—A Pooled Analysis of Two Clinical Trials
EJ Dongelmans, JJ Feld, A Boonstra… - Alimentary …, 2025 - Wiley Online Library
ABSTRACT Background Severe flares (ALT≥ 10× ULN) are a well‐recognised adverse
outcome after nucleos (t) ide analogue (NA) cessation and may lead to liver failure. Thus …
outcome after nucleos (t) ide analogue (NA) cessation and may lead to liver failure. Thus …
Reply to:“The incidence of hepatitis flare and hepatic decompensation after nucleos (t) ide analogue cessation in chronic hepatitis B patients”
EJ Dongelmans, HLA Janssen - Journal of Hepatology, 2024 - journal-of-hepatology.eu
We want to thank dr. Liu and prof. Liaw (2024) for their letter1 regarding our recent
publication about predictors of hepatic flares after nucleos (t) ide analogue (NA) withdrawal …
publication about predictors of hepatic flares after nucleos (t) ide analogue (NA) withdrawal …
More expansive diagnosis and treatment are urgently needed to eliminate the global burden of HBV
Y Liu, X Yuan, F Ji - The Lancet Regional Health–Americas, 2024 - thelancet.com
Worldwide, chronic hepatitis B virus (HBV) infection affected 257.5 million people in 2022,
which contribute to adverse outcomes including cirrhosis, liver failure, and hepatocellular …
which contribute to adverse outcomes including cirrhosis, liver failure, and hepatocellular …